Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy and TPP Insights

Thelansis’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, immune‑mediated neurological disorder in which the body’s immune system attacks the myelin sheath of peripheral nerves, leading to impaired nerve signal transmission and progressive weakness, numbness, tingling, and loss of reflexes that typically evolve over at least eight weeks. Symptoms often affect both proximal and distal muscles, causing difficulty walking, reduced coordination, and fatigue, and the disease may follow a relapsing or steadily progressive course. Diagnosis is based on clinical features, nerve conduction studies showing demyelination, cerebrospinal fluid analysis with elevated protein, and sometimes nerve biopsy, while other causes of neuropathy must be excluded. Treatment aims to suppress the immune attack and improve nerve function, with first‑line options including corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange, while some patients require long‑term immunosuppressive therapy. Although CIDP can cause significant disability, many patients respond well to treatment, especially when recognized early, and prognosis varies from remission to chronic relapsing disease, underscoring the importance of timely diagnosis and individualized management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)